Drug
Sacituzumab Govitecan
Data on this page refer exclusively to patients treated with
Sacituzumab Govitecan combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
ADC group page.
Drug Profile
| Therapeutic Class | Antibody-Drug Conjugates (ADCs) |
| Drug Class | — |
| Group | ADC |
| Mechanism of Action | Trop-2 targeting ADC |
| Half-life | 23,4 h |
